EGFRvIII, a frequently occurring mutation in primary glioblastoma, results in a protein product that cannot bind ligand, but signals constitutively. Deducing how EGFRvIII causes transformation has been difficult because of autocrine and paracrine loops triggered by EGFRvIII alone or in heterodimers with wild-type EGFR. Here, we document coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner. We demonstrate enhancement of downstream STAT signaling triggered by EGFR-catalyzed phosphorylation of EGFRvIII, implicating EGFRvIII as a substrate for EGFR. Subsequent phosphorylation of STAT3 requires nuclear entry of EGFRvIII and formation of an EGFRvIII-STAT3 nuclear complex. Our findings clarify specific oncogenic signaling relationships between EGFR and EGFRvIII in glioblastoma.
INTRODUCTION
The epidermal growth factor receptor (EGFR) plays a prominent role in many tumors including glioblastoma, the most common primary brain tumor. Amplification and overexpression is observed in > 50% of glioblastoma. Half of EGFR-amplified tumors in turn harbor the EGFRvIII mutant, an intragenic rearrangement generated by in-frame deletion of exons 2-7 from this receptor tyrosine kinase (RTK), which consequently signals constitutively in the absence of ligand (Huang et al., 1997; Sugawa et al., 1990; Wong et al., 1992) . A number of studies noted that amplification and overexpression of both EGFR and EGFRvIII conferred a worse prognosis in glioma patients (Heimberger et al., 2005; Shinojima et al., 2003) , with a clinical trial suggesting vaccination against EGFRvIII as a promising immunotherapy (Sampson et al., 2010) . In contrast, a recent report failed to associate amplification of EGFR with outcome (Weller et al., 2009) . Expression of EGFRvIII in glioblastoma is heterogeneous and is usually observed in a subpopulation of neoplastic cells (Nishikawa et al., 2004) . Most antibodies against EGFR and EGFRvIII cross-react, complicating efforts to examine specific coexpression of EGFR or EGFRvIII in individual tumor cells within a glioblastoma.
Does crosstalk occur between EGFR and EGFRvIII signaling? EGFRvIII induces heparin-binding EGF (HB-EGF) in glioma cells.
A neutralizing antibody to HB-EGF blocked EGFRvIII-induced proliferation, raising the possibility of an EGFRvIII-HB-EGF-EGFR autocrine loop in glioblastoma (Inda et al., 2010; Ramnarain et al., 2006) . Expression of EGFRvIII also induces secretion of interleukin-6 and leukemia inhibitory factor. These cytokines activate gp130, generating a paracrine loop that promotes activation of EGFR in neighboring cells (Inda et al., 2010) . Physical interaction of EGFRvIII with EGFR has additionally been proposed, associated with phosphorylation of both EGFRvIII and EGFR (Luwor et al., 2004) . Collectively, these studies suggest paracrine interactions between cells expressing EGFR or EGFRvIII, as well as physical interactions between EGFRvIII and EGFR within individual cells, as contributors to progression in glioma. Here, we analyze coexpression of EGFR and EGFRvIII in primary glioblastoma tumor cells from patients and elucidate functional implications of these findings.
RESULTS

Coexpression of EGFR and EGFRvIII in Human Glioblastoma
Our study demonstrates by immunohistochemistry the expression status of EGFR and EGFRvIII across a series of human primary glioblastoma tissues ( Figure 1A ; Table S1 available online). Table S1 is shown. (B and C) Immunohistochemical staining of a primary human GBM with EGFR-specific (top panel) or EGFRvIII-specific antibody (bottom panel) on consecutive sections (brown, diaminobenzidine; light blue, nuclear counterstain with hemalum) is shown. Black scale bar corresponds to 50 mm. (C) Immunofluorescence double-staining of primary GBM tissue sections using EGFR-specific and EGFRvIII-specific antibodies is shown. Cells double-positive for both EGFR-WT and EGFRvIII are indicated by arrows. An enlarged image of the region marked with a white square (upper-left panel in C) is shown on the right side. Lower panels demonstrate EGFR-WT/EGFRvIII-positive tumor cells in two additional distinct tumors; green fluorescence, EGFR-WT; red fluorescence, EGFRvIII; blue fluorescence, nuclei (4 0 ,6-diamidino-2-phenylindole). White scale bar corresponds to 10 mm. Staining in (A) used pan EGFR antibody (Ventana 790-2988, clone 3C6) and EGFRvIII antibody (Duke University, L8A4). Staining in (B) and (C) used EGFR antibody (Dako DAK-H1-WT) and EGFRvIII antibody (Celldex polyclonal rabbit antiserum 6549). See also Figure S1 and Table S1 .
Among 58 tumors, 83% (48 of 58) stained for EGFR. Of these, 11 (19% of the total) were positive for EGFRvIII, with all EGFRvIII-positive tumors also expressing EGFR. Although these data require that we subtract the EGFRvIII staining from the EGFR/EGFRvIII costained samples (a relatively imprecise process), these data are nevertheless consistent with findings by others (Biernat et al., 2004) and suggest that expression of EGFRvIII typically occurs in glioblastoma tumors that also overexpress EGFR. Representative immunostaining is shown ( Figures S1A-S1F) .
The EGFR antibody used in Figure 1A , Figures S1A-S1F, and Table S1 recognizes both full-length EGFR and EGFRvIII. Therefore, double-immunofluorescence staining experiments were performed using EGFR-and EGFRvIII-specific antibodies. We assessed coexpression of EGFR and EGFRvIII in individual tumor cells in glioblastoma tissue sections from 10 cases previously shown by immunohistochemistry to be positive for both proteins. Representative immunostaining is shown ( Figure 1B) . Antibody specificity is shown in Figure S1G . The majority of cells within tumors coexpressing EGFR and EGFRvIII showed expression of a single RTK. In each sample, however, individual tumor cells or groups of tumor cells were detected that overexpressed both proteins, with EGFR and EGFRvIII colocalized in tumor cells ( Figure 1C ). These results indicate that EGFR and EGFRvIII are jointly overexpressed within subsets of tumor cells in human primary glioblastoma tissue. recapitulate coexpression, we therefore transduced EGFR, EGFRvIII, or both in human glioma cell lines LN-229 and U87MG. Because endogenous EGFR is expressed at low levels in these lines, we also examined mouse NIH 3T3 fibroblast cells, which show little to no expression of EGFR (Bishayee et al., 1999) . EGFR and EGFRvIII cooperated in transformation, forming both significantly more and larger colonies, as compared with parent, EGFR, or EGFRvIII, when expressed in LN-229 cells in the absence of EGF (Figures 2A and 2B (Figures 2A and 2B) . Similar results were obtained in U87MG cells ( Figure S2 ). Importantly, to exclude the possibility that increased transformation was related to doubling of total levels of EGFR/EGFRvIII kinase activity, we also analyzed untransformed NIH 3T3 cells. In these cells (Figure S2 ), EGFR and EGFRvIII synergize in transformation, suggesting a greater than additive effect. Similar results were observed for LN-229 cells in vivo, where EGFR and EGFRvIII led to greater-than-additive effects (compared to LN-229:EGFR or LN-229:EGFRvIII cells) in driving tumor size (Figures 2C and 2D Figure 3A) . STAT signals downstream of EGFR are activated in 60% of glioblastoma patients, drives progression in animal models of glioma, and correlates inversely with survival (Birner et al., 2010; Darnell et al., 1994; Doucette et al., 2012; Shao et al., 2003) , prompting us to analyze this pathway. Addition of EGF led to a statistically significant increase in the abundance of p-STAT3 and p-STAT5 in EGFR/EGFRvIII cells, as compared with parent, EGFR, and EGFRvIII cells ( Figure 3A ; Figure S3) . Induction of p-STAT3 and p-STAT5 in cells coexpressing EGFR/EGFRvIII was also observed in U87MG human glioma and mouse fibroblast NIH 3T3 cells ( Figure S3 ). Higher levels of p-STAT3 and p-STAT5 were also observed in xenografted tumors from LN-229:EGFR/EGFRvIII cells, as compared with parent, EGFR, or EGFRvIII tumors ( Figure 3A) . Interestingly, although levels of p-STAT3 and p-STAT5 were very low in cultured LN-229:EGFRvIII cells, both STAT3 and STAT5 were phosphorylated to a moderate degree in xenografted EGFRvIII tumors (perhaps because of re-expression of EGFR) albeit to lower levels than observed in EGFR/EGFRvIII tumors ( Figure 3A) .
We evaluated whether STAT signaling correlated with coexpression of EGFR and EGFRvIII in human tumors. Analysis of 58 human glioblastoma tumors demonstrated that expression of EGFRvIII was limited to tumors that expressed EGFR (Figure 1A ; Table S1 ). We therefore further analyzed primary human glioblastoma tumors negative for expression of both EGFR and EGFRvIII, positive for EGFR alone, or positive for both EGFR and EGFRvIII. Figure 3B demonstrates that p-STAT3 was expressed at highest levels in primary human tumors that Figure 3C ), with immunofluorescence suggesting some nuclear or perinuclear expression of EGFRvIII ( Figure S3H ) and colocalization of p-STAT3 with EGFRvIII or with EGFR within individual cells ( Figure 3D ). We next examined the kinetics through which EGFR and EGFRvIII could enhance STAT signaling. EGF treatment of LN-229:EGFR/EGFRvIII cells led to prolonged phosphorylation of both EGFR and EGFRvIII, starting at 15 min, continuing through 60 min, and correlating with sustained phosphorylation of STAT3 and STAT5 ( Figure 4A ). In contrast, phosphorylation of EGFR in LN-229:EGFR cells peaked at 30 min, and then declined more rapidly, with less robust peak and temporal phosphorylation of STAT signaling. In LN-229:parent and LN-229: EGFRvIII cells, EGF treatment had little effect on phosphorylation of EGFRvIII, STAT3, or STAT5. Using the protein synthesis inhibitor cycloheximide, we showed similar half-lives for EGFR, EGFRvIII, and STAT3 proteins in LN-229:EGFR/EGFRvIII cells, as compared with parent, EGFR, and EGFRvIII cells ( Figure 4B ), indicating that prolonged temporal phosphorylation of STAT3 in LN-229:EGFR/EGFRvIII cells was independent of receptors and STAT3 stability. These data suggest that EGFR and EGFRvIII coordinately drive enhanced and prolonged STAT phosphorylation.
To address biological effects of EGFRvIII-STAT signaling in human tumors, we queried TCGA data for key expression differences in EGFR/EGFRvIII-coamplified tumors, comparing these to tumors with amplification of EGFR in the absence of EGFRvIII. These data ( Figure S4 ) demonstrate 33 genes that were differentially expressed between the EGFR-EGFRVIII and EGFR-amplified samples. Of note, these genes converge on PKC and PLC, both of which have been previously demonstrated to interact with STAT3 (Lo et al., 2010; McBeth et al., 2013; Parsons et al., 2013) .
EGFR Phosphorylates vIII, Cooperating in
Transformation Surprisingly, the abundance of phosphorylated EGFRvIII was strongly increased when LN-229:EGFR/EGFRvIII cells were treated with EGF ( Figure 3A ), evident at Y1068 and Y1173 tyrosine residues ( Figure S3 ). EGFRvIII is unable to bind ligand and demonstrates constitutive albeit low activity, whereas EGFR shows ligand-dependent signaling. Accordingly, EGF-induced phosphorylation of EGFRvIII in LN-229:EGFR/EGFRvIII cells suggests that EGFR cross-phosphorylates EGFRvIII in response to EGF.
To explore mechanisms through which EGFR could phosphorylate EGFRvIII, we tested analog-sensitive (as) alleles of EGFR, engineered to accept analogs of ATP not efficiently used by wild-type kinases (Bishop et al., 2000; Blair et al., 2007) . NIH 3T3 cells, which have low or undetectable levels of endogenous EGFR (Bishayee et al., 1999) , suggesting retention of basal and EGF-driven kinase activities (Figures 5A and 5B). Treatment with the bulky covalent ATP-analog 4TB [N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)acrylamide (Blair et al., 2007) Figure 5B ). Similarly, in Figure S5 , we set the relative intensity of p-STAT3 in LN-229:EGFR/EGFRvIII cells treated with control siRNA to 100% (after addition of EGF, 15 min, and normalization to GAPDH). The relative intensity of p-STAT3 dropped to 59% in response to EGFRvIII siRNA in Figure S5B and to 55% in Figure S5C , respectively. These data suggest that phosphorylation of EGFRvIII contributes to STAT activation.
We next addressed functional effects of selective EGFR and EGFRvIII inhibition. Consistent with our immunoblot results (Figures 5A and 5B), treatment of EGFR as3 /EGFRvIII cells with 4TB led to decreases in both proliferation and focus formation, inducing arrest at G1. In contrast, 4TB had a modest effect on EGFR/EGFRvIII3 as3 or had little effect on EGFR/EGFRvIII cells, with control EGFR as3 and EGFRvIII as3 cells showing expected responses ( Figure 5C ). Collectively, data in Figure 5 suggest that EGFR phosphorylates EGFRvIII, and that EGFR and EGFRvIII converge to phosphorylate STAT proteins, thereby driving transformation.
EGFRvIII Is a Substrate for EGFR EGFR family members signal through allosteric interactions between monomers, which form an asymmetric dimer. In this dimer, only one kinase is catalytically activated (the receiver kinase), whereas the other functions as the allosteric activator (the activator kinase). To determine whether EGFR and EGFRvIII signal as an asymmetric heterodimer, we generated receiverimpaired (I682Q) and activator-impaired (V924R) mutations in both EGFR and EGFRvIII (Jura et al., 2009 ). LN-229 and NIH 3T3 cells were stably transduced either with single or double retroviral constructs as shown in Figure 6A and Figure S6 . As expected, coexpression of EGFR I682Q and EGFR V924R restored The intensity of each protein, quantified by densitometry using Silver Fast Scanner and ImageJ software, is shown below each immunoblot as fold increase relative to untreated samples (EGF 0 hr or cycloheximide 0 hr) after normalization to GAPDH (bottom panel).
(A) LN-229:parent, LN-229:EGFR, LN-229:EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr and then treated with EGF (50 ng/ml) for the times shown, prior to harvest, lysis, and analysis by immunoblot using the antisera indicated (top panel).
(B) Cells were grown in 10% FBS and then treated with protein synthesis inhibitor cycloheximide (CHX; 50 mg/ml) for the times shown, prior to harvest, lysis, and analysis by immunoblot using the antisera indicated (top panel). EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead. See also Figure S4 .
significant signaling activity, as compared with cells transduced individually with either activator-impaired EGFR V924R or receiverimpaired EGFR I682Q ( Figure S6 ). , downstream signaling from EGFRvIII was restored ( Figure 6B ). Collectively, these data suggest that EGFR and EGFRvIII signal together through a heterodimerization-independent mechanism. Figure S6 . the tails of these two RTKs, phosphorylating STAT proteins, and driving progression in glioblastoma.
EGFR and EGFRvIII Cooperate to Phosphorylate STAT in the Nucleus
To address how EGFR and EGFRvIII converge on STAT signaling, we analyzed subcellular fractions. In the absence of EGF, both EGFR and EGFRvIII were detected in membrane, cytoplasmic, and nuclear extracts in LN-229:EGFR, LN-229:EGFRvIII, and LN-229:EGFR/ EGFRvIII cells ( Figure 7A ). EGF treatment of LN-229:EGFR/EGFRvIII cells resulted in phosphorylation of EGFRvIII in both cytoplasmic and nuclear protein extracts ( Figure 7A ), associated with increased expression of EGFRvIII in the nucleus ( Figure 7A ) and with sustained phosphorylation of STAT3 and STAT5 in the nucleus. In contrast, EGF treatment of LN-229:EGFRvIII cells had little effect on expression of nuclear EGFRvIII, phosphorylation of EGFRvIII, or STAT signaling. EGF treatment only transiently phosphorylated nuclear STAT proteins in LN-229:EGFR cells and had little effect in LN-229:parental cells ( Figure 7A ).
We used densitometry to quantify the relative levels of EGFRvIII phosphorylation in each fraction in LN-229:EGFR/ EGFRvIII cells. The relative intensity of p-EGFRvIII in membrane fractions without EGF stimulation was set to 100% after normalization to b-tubulin from membrane fractions. The relative intensity dropped to 86% after EGF stimulation for 15 min, and to 90% after EGF stimulation for 6 hr. Again, we set the relative intensity of p-EGFRvIII in cytoplasm fractions without EGF stimulation to 100%, after normalization to b-tubulin from cytoplasmic fractions. The relative intensity then increased to 353% after EGF stimulation for 15 min, and to 340% after EGF stimulation for 6 hr. In nuclear fractions, we again set the relative intensity of p-EGFRvIII in nuclear fractions without EGF to 100% after normalization to Lamin B1 from nuclear fractions. The relative intensity increased to 126% after EGF stimulation for 15 min, and to 142% after EGF stimulation for 6 hr. These data suggest that EGF treatment of EGFR/EGFRvIII cells increased phosphorylation of EGFRvIII in cytoplasmic and nuclear fractions, but not in membrane fractions ( Figure 7A ).
To clarify whether EGFRvIII undergoes nuclear translocation to phosphorylate STAT proteins, we transfected LN-229 cells with EGFRvIIIdNLS, an allele of EGFRvIII defective for nuclear entry (Lo et al., 2010) EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr and then treated with EGF (50 ng/ml) for the times shown. Samples were harvested; subject to subcellular fractionation to obtain membrane (M), cytoplasmic (C), and nuclear (N) extracts; and analyzed by immunoblot using the antisera indicated. EGFR is indicated by arrow, whereas EGFRvIII is indicated by arrowhead. (B) LN-229:EGFRvIII, LN-229:EGFRvIIIdNLS, LN-229:EGFR/EGFRvIIIdNLS, or LN-229:EGFR/ EGFRvIII were serum-starved for 24 hr and then treated with EGF (50 ng/ml) for 0 and 15 min. Whole-cell lysates or nuclear extracts were analyzed by immunoblot using the antisera indicated. (C) LN229:parent, LN-229:EGFR, LN-229: EGFRvIII, or LN-229:EGFR/EGFRvIII cells were serum-starved for 24 hr, treated with EGF (50 ng/ml) for 0 and 15 min, and fractionated to obtain nuclear extracts. Nuclear STAT3 was immunoprecipitated using a mouse monoclonal STAT3 antibody, and immunoprecipitates were analyzed by immunoblot to detect EGFR and EGFRvIII (using a rabbit polyclonal EGFR antibody, which recognizes both EGFR and EGFRvIII). Efficacy of subcellular fractionation in (A), (B), and (C) is indicated by membrane and cytoplasmic marker protein b-tubulin, cytoplasmic marker protein GAPDH, and nuclear marker protein Lamin B1. See also Figure S7 . lated STAT proteins as compared to levels in LN-229:EGFR/EGFRvIIIdNLS cells ( Figure 7B ). Consistent with our immunoblot results using whole-cell lysates ( Figure 7B top panel) EGF treatment of LN-229:EGFR/EGFRvIIIdNLS cells resulted in decreased phosphorylation of STAT in the nuclear fraction ( Figure 7B bottom panel) . These data suggest that EGF treatment of EGFR/EGFRvIII cells enhances both nuclear transport of EGFRvIII and phosphorylation of STAT in the nucleus.
We next asked whether nuclear EGFR and EGFRvIII could complex with STAT3 in the nucleus. Nuclear STAT3 was immunoprecipitated and immunoblots analyzed to detect nuclear EGFR and EGFRvIII ( Figure 7C ). Nuclear lysates, whole-cell lysates (input), and nuclear immunoprecipitations are shown in Figure 7C . In LN-229:EGFR/EGFRvIII cells, the levels of nuclear EGFRvIII complexed to STAT3 were enhanced following 15 min of EGF treatment. In contrast, EGF treatment had little effect on the EGFRvIII/STAT3 complex in LN-229:vIII cells. As expected, mouse IgG did not pull down STAT3 or EGFR/EGFRvIII. Collectively, these data suggest that EGFR phosphorylates EGFRvIII, leading to increased nuclear translocation of EGFRvIII and enhanced binding of EGFRvIII to STAT3 in the nucleus.
High STAT3 activity may contribute to resistance of GBM patients to EGFR inhibitors (Mellinghoff et al., 2005; Reardon et al., 2006) . Might inhibition of STAT3 cooperate with inhibition of EGFR in glioma? To partially address this issue, we showed that cells treated with the STAT3 tool inhibitor Stattic in combination with the EGFR inhibitor erlotinib showed differential induction of apoptosis ( Figure S7 ). Baseline levels of apoptosis differ among the four lines, consistent with EGFR and EGFRvIII independently modestly blocking basal apoptosis, with a more prominent effect of EGFR/EGFRvIII in combination. Thus, LN-229:EGFR/EGFRvIII cells at baseline showed 2.1% apoptosis, compared to 44.8% in response to Stattic and erlotinib (21-fold change). LN-229:EGFRvIII cells at baseline showed 3.4% apoptosis, compared to 46.9% in response to Stattic and erlotinib (14-fold change). By comparison, LN-229:EGFR cells at baseline showed 4.3% apoptosis, compared to 40.6% in response to Stattic and erlotinib (9-fold change), while LN-229:parent cells at baseline showed 6.8% apoptosis, compared to 42.1% in response to Stattic and erlotinib (6-fold change). These data suggest cooperative blockade of EGFR and STAT3 as a developmental therapeutic strategy in EGFR/EGFRvIII coamplified glioma.
DISCUSSION
Amplification and overexpression of EGFR represent striking features of primary glioblastoma, with frequent coamplification of EGFR and its deletion mutant, EGFRvIII (Huang et al., 1997; Sugawa et al., 1990; Wong et al., 1992) . Using immunofluorescence double staining with EGFR-and EGFRvIII-specific antibodies, we demonstrate that EGFR and EGFRvIII colocalize within individual tumor cells in glioblastoma. We further highlight cooperation between EGFR and EGFRvIII in transformation in vivo, with cell-based experiments showing that EGF treatment of cells expressing both EGFR and EGFRvIII resulted in phosphorylation of both kinases. This result was unexpected because EGFRvIII is unable to bind or be activated in response to EGF. Using chemical genetic approaches, we found that EGFR promoted unidirectional EGFRvIII signaling in glioblastoma cells, driving further phosphorylation of STAT proteins and enhanced malignancy. It is intriguing that enhanced STAT signaling is so selectively affected by EGFR/EGFRvIII crosstalk, whereas signaling through PI3K and MAPK is less prominently affected. In addition, STAT signaling has been suggested to feature prominently in glioma stem cells (Guryanova et al., 2011) . That rare cells within GBM tumors coamplify EGFR and EGFRvIII and phosphorylate STAT3 could be consistent with a role for STAT3 activation within the stem cell compartment of GBM.
How does EGFR activate EGFRvIII? Whereas others have demonstrated physical binding of these two kinases, our coimmunoprecipitation experiments failed to demonstrate this interaction. We were similarly unable to reconstitute signaling in a heterodimeric complex where EGFR was an obligate allosteric activator and EGFRvIII an obligate receiver. Kinasedead EGFRvIII was readily phosphorylated by EGFR, suggesting EGFRvIII as a substrate of EGFR. Phosphorylation of both EGFR and EGFRvIII were required to fully phosphorylate STAT proteins. EGFR, when expressed alone, led to lower level and shorter duration of STAT phosphorylation, as compared to levels and duration observed in cells coexpressing both EGFR and EGFRvIII. Further, coexpression of EGFR with EGFRvIII DY5 , a mutant in which tyrosines in the tail of EGFRvIII were replaced with phenylalanines, blunted phosphorylation of STAT3 protein.
Analysis of human glioblastoma tumors demonstrated alignment among EGFR, EGFRvIII, and STAT signaling in tumors, supporting a model in which EGFR activation of EGFRvIII leads to transphosphorylation of both kinases, converging on STAT signaling. Using subcellular fractionation, we further demonstrated that EGFR phosphorylation of EGFRvIII led to nuclear transport of EGFRvIII and enhanced the formation of a complex between EGFRvIII and STAT3 in the nucleus. These data suggest that EGFR and EGFRvIII coordinately drive enhanced and prolonged STAT activity in the nucleus. It remains possible, however, that very high levels of EGFR could subserve this role even in the absence of EGFRvIII.
In this study, we identify an EGFR-EGFRvIII-STAT signaling axis in a subset of glioblastomas that coamplify EGFR and EGFRvIII within individual tumor cells. Given that coexpressed EGFR and EGFRvIII and high levels of STAT signaling may confer both more aggressive behavior in glioblastoma (Abou-Ghazal et al., 2008; Birner et al., 2010; Shinojima et al., 2003) , our findings suggest targeting EGFR in conjunction with STAT signaling as a therapeutic strategy for patients with EGFRvIII-positive glioblastoma.
EXPERIMENTAL PROCEDURES Tumor Samples
Primary tumor samples were obtained in accordance with research ethics board approval from UCSF and the Heinrich Heine University. Informed consent was obtained from all UCSF patients. Archival samples from Dü sseldorf were investigated in an anonymized manner, approved by the ethics committee of the Medical Faculty of Heinrich Heine University.
Construction of EGFR and EGFRvIII Mutants
Retroviral-based pWLZ-hygro-EGFR-as3 was described previously (Blair et al., 2007) . pWLZ-hygro-EGFRas3 plasmid was digested with BstXI and ligated into a similarly digested pLRNL-neo-EGFRvIII plasmid, generating retroviral-based pLRNL-neo-EGFRvIII-as3, an analog-sensitive allele of EGFRvIII. pLRNL-neo-EGFRvIII DY5 (Johns et al., 2007) and pCMV-tag5A-EGFRvIIIdNLS (Lo et al., 2010) were generously provided by Drs. Frank Furnari and Hui-Wen Lo, respectively. Point mutations (I682Q and V924R) were engineered into the pWLZ-hygro-EGFR or into the pLRNL-neo-EGFRvIII by sitedirected mutagenesis (QuickChange Mutagenesis kit, Stratagene). All primer sequences are in Thiel and Carpenter (2007) . Point mutation pcDNA-neo-EGFR (D813N) plasmid was from Natalia Jura, UCSF; digested with BstXI; ligated into a similarly digested vector; and used to generate either pWLZhygro-EGFR (D813N) or pLRNL-neo-EGFRvIII (D813N). All mutants were sequence validated. Cell Lines, Reagents, Transfection, and Transduction Human glioma cell lines LN-229 and U87MG were obtained from the Brain Tumor Research Center at UCSF. NIH 3T3 mouse fibroblasts were from ATCC. These and derivate lines were grown in 0.5% or 10% FBS. To generate retrovirus, the packaging cell line 293T was cotransfected with plasmids gag/pol and VSVg, using Effectene-transfection reagent (QIAGEN). High-titer virus was collected at 48 hr and used to infect cells as previously described . pCMV-tag5A-EGFRvIIIdNLS plasmid was generously provided by Dr. Hui-Wen Lo, Duke University, and transfected into LN-229:parent or LN-229:EGFR cells. Transfected and transduced cells were selected as pools with G418 (800 mg/ml) or hygromycin (500 mg/ml) for 2 weeks. EGF was from Roche. Cyclohexmide and Stattic were from Sigma. 4TB [N-(4-(4-tert-butylphenylamino)quinazolin-6-yl)] acrylamide were synthesized as described (Blair et al., 2007) .
Immunohistochemical Analyses
Immunohistochemical staining was performed by the UCSF Neurosurgery Tissue Core. Paraffin-embedded sections (5 mm) of human GBM were immunostained on the Benchmark XT automated stainer (Ventana Medical System). Antibodies were detected with the Ventana iVIEW DAB detection kit (yielding a brown reaction product). The EGFR antibody utilized in this study was a mouse monoclonal antibody obtained from Ventana 790-2988 (clone 3C6), which recognizes the extracellular domain of both full-length and the EGFRvIII variant of EGFR and was supplied as part of an FDA-validated clinical diagnostic kit for EGFR abundance, used clinically to assess EGFR status. The EGFRvIII mouse monoclonal antibody was from Duke University (L8A4). Slides were counterstained with hematoxylin. Immunostaining results were graded in a semiquantitative manner by determining the intensity of staining of each section and grading from 0 (no staining), 1 (1-25% immunoreactivity of cells), 2 (26-75% immunoreactivity), to 3 (>75% immunoreactivity). Human glioblastoma tissue samples were routinely fixed in 4% buffered formaldehyde and embedded in paraffin. Five-micron-thick tissue sections were deparaffinized in xylene and rehydrated over a graded ethanol series. For antigen retrieval, rehydrated sections were treated in 10 mM citrate buffer at pH 6.0 (for EGFRvIII and p-STAT3) or at pH 9.0 (for EGFR) for 20 min in a steamer. Sections were immunostained with antibodies against EGFR (mouse monoclonal DAK-H1-WT; Dako; diluted 1:200), EGFRvIII (rabbit polyclonal 6549; Celldex; diluted 1:5000), or p-STAT3 (Tyr705) (rabbit monoclonal antibody D3A7 or mouse monoclonal antibody 3E2; Cell Signaling; each diluted 1:50). Immunohistochemistry was performed on the Dako Autostainer Plus automated slide-processing system using the Ultravision LP Large Volume Detection System HRP Polymer (Thermo Scientific) for detection of antibody binding according to the manufacturer's protocol. 3,3-Diaminobenzidine was used as substrate for the peroxidase reaction. Slides were counterstained with hemalum, dehydrated, and mounted in DePeX (Serva) mounting medium.
Double-Immunofluorescence Analyses
Glioma cells grown as monolayer cultures on chamber slides were fixed with methanol. Formalin-fixed paraffin sections from primary tumor tissues were deparaffinized in xylene and rehydrated over a graded ethanol series, followed by treatment in 10 mM citrate buffer at pH 6.0 for 20 min in a steamer for antigen retrieval. Rehydrated fixed cells and tissue sections were blocked 5 min with Ultra V Block (Thermo Scientific) and incubated overnight at 4 C with primary antibodies against EGFR (mouse monoclonal DAK-H1-WT; Dako) and EGFRvIII (rabbit polyclonal 6549; Celldex) diluted 1:50. Additional double-labeling experiments were performed with antibodies against EGFR and p-STAT3 (Tyr705) antibody (rabbit monoclonal antibody D3A7; Cell Signaling) or antibodies against EGFRvIII and p-STAT3 (Tyr705) antibody (mouse monoclonal antibody 3E2; Cell Signaling). Three washing steps were followed by incubation at room temperature for 1 hr with Alexa Fluor 488/594 secondary antibodies (Invitrogen) diluted 1:500. Following repeated washing, stained sections and cells were mounted in ProLong Gold antifade reagent (Invitrogen) with DAPI.
In Vitro and In Vivo Growth Assays
We used the Cell Transformation Detection Assay kit (Millipore) to evaluate colony formation on soft agar. Briefly, plates were precoated with 0.7% agarose as the bottom layer. Cells were seeded at a density of 1 3 10 4 cells per six wells in triplicate for each cell line and cultured in 0.35% agarose as the top layer in DMEM (without phenol red) plus 10% FBS at 37 C for 3 weeks. The cells were kept wet by adding a small amount of culture media. EGF (50 ng/ml) was added every 5 days. Colonies were stained overnight at 37 C (Cell Transformation Detection Assay kit; Millipore 
Subcellular Fractionation and Immunoprecipitation
For multicompartmental fractionation of cells we used the subcellular protein fractionation kit (Thermo Scientific Pierce) according to the manufacturer's instructions. For immunoprecipitation, 200 mg nuclear protein were incubated with 1 mg anti-STAT3 mouse monoclonal antibody (Cell Signaling) or control mouse IgG at 4 C overnight with gentle agitation. Following addition of 20 ml protein G-agarose and incubation for 1 hr at 4 C, the immunocomplexes were pelleted, washed for multiple cycles at 4 C, and then subjected to SDS-PAGE and western blotting analysis probing for EGFR (rabbit antibody that recognizes both EGFR and EGFRvIII; Santa Cruz Biotechnology). 
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